FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical combination comprising phosphatidylinositol-3-kinase (PI3K) inhibitor compound of formula (I) as defined herein or a pharmaceutically acceptable salt thereof and paclitaxel or a pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use in the treatment of head and neck cancer; pharmaceutical composition comprising said combination; use of said combination for the preparation of a medicament for the treatment of head and neck cancer; method for treating or preventing head and neck cancer comprising administering together a therapeutically effective amount of a combination to a subject in need thereof.
EFFECT: combination of a PI3 kinase inhibitor with paclitaxel has been proposed for use in the treatment or prevention of head and neck cancer.
15 cl, 2 ex, 1 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME | 2021 |
|
RU2821030C1 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| COMBINATION OF PD-1 ANTAGONIST AND IDO1 INHIBITOR FOR TREATING ANCER | 2015 |
|
RU2744880C1 |
| COMBINATION OF OZOGAMICIN INOTUZUMAB AND TORIZEL FOR TREATING CANCER | 2012 |
|
RU2607594C2 |
| COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
| COMPOSITION COMPRISING N-{5-[4-(4-METHYLPIPERAZINOMETHYL)BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRILYL)-2-PYRIDINEAMINE AND CHEMOTHERAPEURIC AGENT | 2002 |
|
RU2318517C2 |
| COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
